Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole for agitation in Alzheimer's dementia
NCT03620981Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole orally disintegrating tablet in Alzheimer's disease (AD) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Cohen-Mansfield Agitation Inventory Score at 10 weeks. Started Aug 2018; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03620981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620981.